Alzheimer's vaccine study for healthy adults ages 40 to 65
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an experimental vaccine (DUVAX) that targets two proteins linked to Alzheimer's disease: amyloid-beta and tau. It is an early-stage study to check safety and see how the body responds, aiming to prevent or delay the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Healthy men or non-pregnant women, ages 40 to 65 years old
- Body mass index (BMI) between 18 and 32
- No major health problems like uncontrolled blood pressure, heart issues, or serious illnesses
- No recent (within 1 year) treatment with similar Alzheimer's vaccines or immune therapies
- No MRI brain scan abnormalities (like strokes or bleeding spots) that would interfere
- Willing to use effective birth control (women) or condoms / no sperm donation (men) during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a vaccine that targets tau protein, which is linked to Alzheimer's disease. It is for older adults who have no memory problems yet but have biological signs of early Alzheimer's, to see if the vaccine can prevent or slow down the disease.
This trial tests a vaccine that may help the immune system clear a protein linked to Alzheimer's disease. It is for people who do not have memory problems yet but have signs of the disease in their blood or brain scans.
This trial tests a vaccine that targets tau tangles in the brain, which are linked to Alzheimer's. It is part of a larger platform study that combines different experimental treatments.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.